| Michael Robert Aho, MD | |
|
1700 Medical Way, Snellville, GA 30078-2195 | |
| (770) 979-0200 | |
| (770) 736-2335 |
| Full Name | Michael Robert Aho |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 16 Years |
| Location | 1700 Medical Way, Snellville, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477729051 | NPI | - | NPPES |
| 068976 | Other | GA | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 68976 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastside Medical Center | Snellville, GA | Hospital |
| Northside Hospital | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Gwinnett Radiology Pc | 5496710493 | 8 |
News Archive
Driver genes in different metastases from the same patient are remarkably similar, providing optimism for the success of future targeted therapies, according to a published study by Science.
A new "thought paper" created by one of the healthcare industry's leading business development organizations cautions hospitals against taking a wait-and-see approach to healthcare reform if they are to have a role in determining their own destiny.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 5 days ago
| Entity Name | Emory Medical Care Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063452381 PECOS PAC ID: 4981501814 Enrollment ID: O20031217000968 |
News Archive
Driver genes in different metastases from the same patient are remarkably similar, providing optimism for the success of future targeted therapies, according to a published study by Science.
A new "thought paper" created by one of the healthcare industry's leading business development organizations cautions hospitals against taking a wait-and-see approach to healthcare reform if they are to have a role in determining their own destiny.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 5 days ago
| Entity Name | Northside Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013960657 PECOS PAC ID: 4486555398 Enrollment ID: O20040115000095 |
News Archive
Driver genes in different metastases from the same patient are remarkably similar, providing optimism for the success of future targeted therapies, according to a published study by Science.
A new "thought paper" created by one of the healthcare industry's leading business development organizations cautions hospitals against taking a wait-and-see approach to healthcare reform if they are to have a role in determining their own destiny.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 5 days ago
| Entity Name | South Gwinnett Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740232677 PECOS PAC ID: 5496710493 Enrollment ID: O20041201000165 |
News Archive
Driver genes in different metastases from the same patient are remarkably similar, providing optimism for the success of future targeted therapies, according to a published study by Science.
A new "thought paper" created by one of the healthcare industry's leading business development organizations cautions hospitals against taking a wait-and-see approach to healthcare reform if they are to have a role in determining their own destiny.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Robert Aho, MD Po Box 116075, Atlanta, GA 30368-6075 Ph: (855) 709-1801 | Michael Robert Aho, MD 1700 Medical Way, Snellville, GA 30078-2195 Ph: (770) 979-0200 |
News Archive
Driver genes in different metastases from the same patient are remarkably similar, providing optimism for the success of future targeted therapies, according to a published study by Science.
A new "thought paper" created by one of the healthcare industry's leading business development organizations cautions hospitals against taking a wait-and-see approach to healthcare reform if they are to have a role in determining their own destiny.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
PolyMedix, Inc. has received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared to enter human clinical trials for systemic use, representing an entirely new class of antibiotic drugs.
› Verified 5 days ago
Charlotte A Hayes, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Way, Snellville, GA 30078 Phone: 770-979-0200 | |
Mr. Gautam Jagoo, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Way, Snellville, GA 30078 Phone: 770-979-0200 | |
Arvind Sivakumaran, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Way, Snellville, GA 30078 Phone: 770-979-0200 Fax: 770-736-2335 | |
Robert J Kubek, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Way, Snellville, GA 30078 Phone: 770-979-0200 | |
Gregory S. Berkey, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Way, Snellville, GA 30078 Phone: 770-979-0200 | |
Dr. Shailaja R. Sappati, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Way, Snellville, GA 30078 Phone: 770-979-0200 Fax: 770-736-2335 |